Thelansis

Chronic Spontaneous Urticaria (CSU) Emerging Therapy and TPP Insights Thelansis’s “Chronic Spontaneous Urticaria (CSU) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Chronic Spontaneous Urticaria (CSU) Overview Chronic spontaneous urticaria, also known as chronic idiopathic urticaria, is defined as the presence of wheals, as well as possibly associated angioedema, for six weeks or longer in the absence of known triggering factors. The condition is known to last for a period of time, averaging five years, but can last longer in severe cases, especially if accompanied by angioedema. In addition, a great level of disability, reduced productivity, as well as an increased risk of psychological co-morbidities, is observed in these p...

Chronic Spontaneous Urticaria (CSU) Emerging Therapy and TPP Insights Thelansis’s “Chronic Spontaneous Urticaria (CSU) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target P...